摘要
目的了解本院护肝药物的应用现状及发展趋势,为临床合理用药提供参考。方法采用销售金额排序法和用药频度分析法对本院2014~2015年护肝药物的应用情况进行统计分析,并对销售前列的药物进行处方点评,对药物的安全性及有效性进行评价。结果 2014~2015年间,舒肝宁、复方二氯醋酸二异丙胺注射液、甲硫氨酸维B1DDDs排序变化较大,其中异甘草酸镁的上升幅度较大,护肝药物在感染疾病科、肝胆胰脾科以及血液科等13个科室的应用频率较高,其中血液科达到了40.68%。护肝药物使用后常见的不良反应为恶心、呕吐、皮炎、皮疹等。结论院内护肝药物种类较多,且作用效果不尽相同,其中最新一代甘草酸制剂异甘草酸镁的药频度一直稳居前列,且其安全性和有效性得到临床医师的一致认可。
Objective To investigate the application status and development trend of hepatoprotective drugs in our hospital, and to provide reference for clinical rational drug use. Methods The order of sales amount and frequency of drug use were used to analyze the application of hepatoprotective drugs in our hospital from 2014 to 2015. The prescription of the drug was evaluated and the safety and effectiveness of the drug were evaluated. Results The order of B1 DDDs of Shuganning, compound dichloroacetic acid diisopropylamine injection and methionine dimension changed from 2014 to 2015, and magnesium isoglycyrrhizinate increased in the range of infectious diseases, hepatobiliary and pancreatic spleen and hematology and other 13 departments of the application of a higher frequency, which reached 40.68% of hematology. Commonly used adverse drug reactions after nausea, vomiting, dermatitis, rash and so on. Conclusion There are many types of hepatoprotective drugs in the hospital, and the effect is different. The latest generation of glycyrrhizin preparations has been ranked the forefront of the drug, and its safety and efficacy have been recognized by the clinicians, which can be used as clinical medicine. Liver protection drugs of choice.
出处
《中国继续医学教育》
2016年第33期168-170,共3页
China Continuing Medical Education
关键词
肝病
护肝药物
用药分析
Liver disease
Liver protection drugs
Drug analysis
